Sepsis - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 240
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S107D2E0A5EEN
Leaflet:

Download PDF Leaflet

Sepsis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Sepsis - Pipeline Review, H2 2016’, provides an overview of the Sepsis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Sepsis
  • The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
  • The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sepsis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sepsis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Sepsis Overview
Therapeutics Development
Pipeline Products for Sepsis - Overview
Pipeline Products for Sepsis - Comparative Analysis
Sepsis - Therapeutics under Development by Companies
Sepsis - Therapeutics under Investigation by Universities/Institutes
Sepsis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Sepsis - Products under Development by Companies
Sepsis - Products under Investigation by Universities/Institutes
Sepsis - Companies Involved in Therapeutics Development
Adrenomed AG
Altor BioScience Corporation
Am-Pharma B.V.
Arch Biopartners, Inc.
Aridis Pharmaceuticals LLC
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Batu Biologics, Inc.
Biomedica Management Corporation
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cell2B S.A.
Chiesi Farmaceutici SpA
Chiome Bioscience, Inc.
Cilian AG
Cognosci, Inc.
Cytheris SA
Endacea, Inc.
Evec, Inc.
Huons Co., Ltd.
Immune Response BioPharma, Inc.
Immunethep, SA
ImmunNovative Developments SL
InflaRx GmbH
Inotrem S.A.
Integrated BioTherapeutics, Inc.
Lead Discovery Center GmbH
Merck & Co., Inc.
Navigen Pharmaceuticals, Inc.
OncoImmune, Inc.
Opsona Therapeutics Limited
Orion Oyj
ProThera Biologics, LLC.
Ra Pharmaceuticals, Inc.
Recce Pty Ltd
Ribomic Inc.
Shionogi & Co., Ltd.
Silence Therapeutics Plc
SK Biopharmaceuticals Co., Ltd.
Stemedica Cell Technologies, Inc.
Syntiron LLC
TaiRx, Inc.
Takeda Pharmaceutical Company Limited
Therakind Limited
Therashock, LLC
TiGenix NV
VBS Pharmaceuticals
ViiV Healthcare Limited
XImmune AB
Sepsis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles

3K3A-APC - DRUG PROFILE 91


7-H9 - DRUG PROFILE 93

AB-022 - Drug Profile
AcPepA - Drug Profile
adrecizumab - Drug Profile
ALT-836 - Drug Profile
AM/AMBP-1 - Drug Profile
Aspidasept - Drug Profile
Atu-111 - Drug Profile
BI-113823 - Drug Profile
Biologic to Inhibit PD-L1 for Immunology - Drug Profile
BMS-936559 - Drug Profile
BMS-986189 - Drug Profile
BRL-44408 - Drug Profile
BTZO-2 - Drug Profile
CAR Peptide - Drug Profile
ceftaroline fosamil - Drug Profile
COG-133 - Drug Profile
Cx-611 - Drug Profile
CYT-107 - Drug Profile
Drug for Sepsis and Septic Shock - Drug Profile
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
Drugs to Inhibit Sialidase for Sepsis - Drug Profile
Escherichia coli vaccine - Drug Profile
ethinyl estradiol sulfonate - Drug Profile
EV-007156 - Drug Profile
Gamma-PN - Drug Profile
Glyco-23 - Drug Profile
HBN-1 - Drug Profile
HBN-3 - Drug Profile
HBN-4 - Drug Profile
HU-003 - Drug Profile
IFX-1 - Drug Profile
ImmStem - Drug Profile
ImmuneSafe - Drug Profile
IMT-504 - Drug Profile
IND-006 - Drug Profile
IR-999 - Drug Profile
Klebsiella pneumoniae vaccine - Drug Profile
L-257 - Drug Profile
L-97-1 - Drug Profile
L-Citrulline - Drug Profile
levosimendan - Drug Profile
M-33 - Drug Profile
M-6229 - Drug Profile
meropenem - Drug Profile
Metablok - Drug Profile
Micselon - Drug Profile
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile
Motrem - Drug Profile
NAV-838 - Drug Profile
OPN-305 - Drug Profile
OTP-300 - Drug Profile
Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile
PNV-1 - Drug Profile
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
RA-101295 - Drug Profile
RBM-005 - Drug Profile
RECCE-327 - Drug Profile
Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile
Recombinant Protein for Sepsis - Drug Profile
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile
S-649266 - Drug Profile
SAN-101 - Drug Profile
Slit2N - Drug Profile
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
Staphylococcus aureus (multivalent) vaccine - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile
Synthetic Peptides for Infectious Disease - Drug Profile
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile
Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile
TF-0003 - Drug Profile
thrombomodulin alfa - Drug Profile
tosatoxumab - Drug Profile
TRX-306 - Drug Profile
vancomycin hydrochloride - Drug Profile
Yersinia pestis vaccine - Drug Profile
Sepsis - Dormant Projects
Sepsis - Discontinued Products
Sepsis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sepsis, H2 2016
Number of Products under Development for Sepsis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Sepsis - Pipeline by Adrenomed AG, H2 2016
Sepsis - Pipeline by Altor BioScience Corporation, H2 2016
Sepsis - Pipeline by Am-Pharma B.V., H2 2016
Sepsis - Pipeline by Arch Biopartners, Inc., H2 2016
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Sepsis - Pipeline by Astellas Pharma Inc., H2 2016
Sepsis - Pipeline by Batu Biologics, Inc., H2 2016
Sepsis - Pipeline by Biomedica Management Corporation, H2 2016
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Sepsis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Sepsis - Pipeline by Cell2B S.A. , H2 2016
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2016
Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2016
Sepsis - Pipeline by Cilian AG, H2 2016
Sepsis - Pipeline by Cognosci, Inc., H2 2016
Sepsis - Pipeline by Cytheris SA, H2 2016
Sepsis - Pipeline by Endacea, Inc., H2 2016
Sepsis - Pipeline by Evec, Inc., H2 2016
Sepsis - Pipeline by Huons Co., Ltd., H2 2016
Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2016
Sepsis - Pipeline by Immunethep, SA, H2 2016
Sepsis - Pipeline by ImmunNovative Developments SL, H2 2016
Sepsis - Pipeline by InflaRx GmbH, H2 2016
Sepsis - Pipeline by Inotrem S.A., H2 2016
Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2016
Sepsis - Pipeline by Merck & Co., Inc., H2 2016
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
Sepsis - Pipeline by OncoImmune, Inc., H2 2016
Sepsis - Pipeline by Opsona Therapeutics Limited, H2 2016
Sepsis - Pipeline by Orion Oyj, H2 2016
Sepsis - Pipeline by ProThera Biologics, LLC., H2 2016
Sepsis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
Sepsis - Pipeline by Recce Pty Ltd, H2 2016
Sepsis - Pipeline by Ribomic Inc., H2 2016
Sepsis - Pipeline by Shionogi & Co., Ltd., H2 2016
Sepsis - Pipeline by Silence Therapeutics Plc, H2 2016
Sepsis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
Sepsis - Pipeline by Syntiron LLC, H2 2016
Sepsis - Pipeline by TaiRx, Inc., H2 2016
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Sepsis - Pipeline by Therakind Limited, H2 2016
Sepsis - Pipeline by Therashock, LLC, H2 2016
Sepsis - Pipeline by TiGenix NV, H2 2016
Sepsis - Pipeline by VBS Pharmaceuticals, H2 2016
Sepsis - Pipeline by ViiV Healthcare Limited, H2 2016
Sepsis - Pipeline by XImmune AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Sepsis - Dormant Projects, H2 2016
Sepsis - Dormant Projects (Contd..1), H2 2016
Sepsis - Dormant Projects (Contd..2), H2 2016
Sepsis - Dormant Projects (Contd..3), H2 2016
Sepsis - Dormant Projects (Contd..4), H2 2016
Sepsis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Sepsis, H2 2016
Number of Products under Development for Sepsis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 24 pages
Cilian AG - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 26 pages
Hyperglycemia - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 38 pages

Ask Your Question

Sepsis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: